ResMed (RMD)
(Real Time Quote from BATS)
$189.40 USD
+0.05 (0.03%)
Updated Jul 3, 2024 03:32 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
RMD 189.40 +0.05(0.03%)
Will RMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RMD
Omnicell (OMCL) Banks on Product Launches, Global Growth
Zacks.com featured highlights include ResMed, Badger Meter, Leidos and Ingersoll Rand
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs
4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
Other News for RMD
10 Health Care Stocks Whale Activity In Today's Session
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
Disney, MicroStrategy initiated: Wall Street's top analyst calls
Beyond The Numbers: 6 Analysts Discuss ResMed Stock
Oppenheimer downgrades ResMed on sleep apnea GLP-1 risk